Genotyping for human platelet alloantigen polymorphisms: Applications in the diagnosis of alloimmune platelet disorders

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 6, 2008, Pages 539-548

  Curtis, Brian R ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Fetal and neonatal alloimmune thrombocytopenia; Human platelet antigens; Platelet antibodies; Platelet genotyping; Posttransfusion purpura

Indexed keywords

ALLOANTIGEN; THROMBOCYTE ANTIGEN;

AUTOIMMUNITY; DRUG INDUCED IMMUNE THROMBOCYTOPENIA; FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; GENE; GENETIC ANALYSIS; GENOTYPE; HUMAN; MULTIPLATELET TRANSFUSION REFRACTORINESS; POLYMERASE CHAIN REACTION; POSTTRANSFUSION PURPURA; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PURPURA; REVIEW; THROMBOCYTOPENIA;

ANTIGENS, HUMAN PLATELET; AUTOANTIBODIES; BLOOD PLATELETS; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; ISOANTIBODIES; PLATELET TRANSFUSION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 57149108912     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1103365     Document Type: Review

References (70)

1. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-1781
2. McFarland JG, Aster RH, Bussel JB, Gianopoulos JG, Derbes RS, Newman PJ. Prenatal diagnosis of neonatal alloimmune thrombocytopenia using allele-specific oligonucleotide probes. Blood 1991;78:2276-2282
3. Beiboer SH, Wieringa-Jelsma T, Maaskant-Van Wijk PA et al.. Rapid genotyping of blood group antigens by multiplex polymerase chain reaction and DNA microarray hybridization. Transfusion 2005;45:667-679
4. Denomme GA, Van Oene M. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes. Transfusion 2005;45:660-666
5. Hashmi G, Shariff T, Seul M, et al. A flexible array format for large-scale, rapid blood group DNA typing. Transfusion 2005;45:680-688
6. Stein EL, Santoso S, Behrens G, Mueller-Eckhardt C, Bux J. Genotyping of the granulocyte-specific NA antigens from small quantities of blood or serum. Tissue Antigens 1995;45:69-72
7. Hessner MJ, Curtis BR, Endean DJ, Aster RH. Determination of neutrophil antigen gene frequencies in five ethnic groups by polymerase chain reaction with sequence-specific primers. Transfusion 1996;36:895-899
8. Bux J. Molecular nature of granulocyte antigens. Transfus Clin Biol 2001;8:242-247
9. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003;85:240-245
10. Bertrand G, Bianchi F, Alexandre M, et al. HPA-13bw neonatal alloimmune thrombocytopenia and low frequency alloantigens: case report and review of the literature. Transfusion 2007;47:1510-1513
11. Peterson JA, Gitther M, Pietz BC, Johnson SC, Balthazor SM, Aster RH. Rare antigens in neonatal alloimmune thrombocytopenia. J Thromb Haemost 2007;5(suppl):O-T-028 (Abst)
12. Curtis BR, McFarland JG. Platelet immunology and alloimmunization. In: Simon TL, Dzik WH, Snyder E, Stowell CP, Strauss RG, eds. Rossi's Principles of Transfusion Medicine. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:203-217
13. Curtis BR, Ali S, Glazier AM, Ebert DD, Aitman TJ, Aster RH. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002;42:1173-1179
14. Curtis BR, Donnelly SF, Mintz PD, Boos VX, Hetzel SL, Aster RH. Platelet transfusion refractoriness in a African American patient due to ant-Nak(a). Transfusion 1997;37(suppl):96S (Abst)
15. Beyer GM, Martin MA, Nash T, Curtis BR, Harrison CR. Platelet refractoriness secondary to platelet specific antibody against glycoprotein IV (CD36). Transfusion 2007;47(suppl):196A (Abst)
16. Bierling P, Godeau B, Fromont P, et al. Posttransfusion purpura-like syndrome associated with CD36 (Naka) isoimmunization. Transfusion 1995;35:777-782
17. Slichter SJ. Platelet refractoriness and alloimmunization. Leukemia 1998;12(Suppl 1):S51-S53
18. Hurd CM, Cavanagh G, Schuh A, Ouwehand WH, Metcalfe P. Genotyping for platelet-specific antigens: techniques for the detection of single nucleotide polymorphisms. Vox Sang 2002;83:1-12
19. Skogen B, Bellissimo DB, Hessner MJ, et al. Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers. Transfusion 1994;34:955-960
20. Nauck MS, Gierens H, Nauck MA, Marz W, Wieland H. Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labelled hybridization probes on the Light-Cycler. Br J Haematol 1999;105:803-810
21. Kretzschmar E, Von Ahsen N, Trobisch H. Rapid genotyping of human platelet antigen 5 with fluorophore-labelled hybridization probes on the LightCycler. Br J Haematol 2001;114:397-399
22. Randen I, Sorensen K, Killie MK, Kjeldsen-Kragh J. Rapid and reliable genotyping of human platelet antigen (HPA)-1, -2, -3, -4, and -5 a/b and Gov a/b by melting curve analysis. Transfusion 2003;43:445-450
23. Kjaer KM, Jaegtvik S, Husebekk A, Skogen B. Human platelet antigen 1 (HPA 1) genotyping with 5′ nuclease assay and sequence-specific primers reveals a single nucleotide deletion in intron 2 of the HPA 1a allele of platelet glycoprotein IIIa. Br J Haematol 2002;117:405-408
24. Bugert P, McBride S, Smith G, et al. Microarray-based genotyping for blood groups: comparison of gene array and 5′-nuclease assay techniques with human platelet antigen as a model. Transfusion 2005;45:654-659
25. Wu YY, Csako G. Rapid and/or high-throughput genotyping for human red blood cell, platelet and leukocyte antigens, and forensic applications. Clin Chim Acta 2006;363:165-176
26. Avent ND. Large scale blood group genotyping. Transfus Clin Biol 2007;14:10-15
27. Curtis BR, Fick A, Lochowicz AJ, et al. Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion 2008;48:358-364
28. Quill E. Medicine. Blood-matching goes genetic. Science 2008;319:1478-1479
29. Peterson JA, Balthazor SM, Curtis BR, McFarland JG, Aster RH. Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion 2005;45:1487-1495
30. Kaplan C, Porcelijn L, Vanlieferinghen P, et al. Anti-HPA-9bw (Max a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families. Transfusion 2005;45:1799-1803
31. Bertrand G, Bianchi F, Chenet C, et al. New mutation in the platelet beta3-integrin gene: implication for the diagnosis of fetomaternal alloimmunization. Transfusion 2006;46:2138-2141
32. Skogen B, Wang R, McFarland JG, Newman PJ. A dinucleotide deletion in exon 4 of the PlA2 allelic form of glycoprotein IIIa: implications for the correlation of serologic versus genotypic analysis of human platelet alloantigens. Blood 1996;88:3831-3836
33. Smith GA, Rankin A, Riddle C, et al. Severe fetomaternal alloimmune thrombocytopenia due to anti-human platelet antigen (HPA)-1a in a mother with a rare and silenced ITGB3*0101 (GPIIIa) allele. Vox Sang 2007;93:325-330
34. Watkins NA, Schaffner-Reckinger E, Allen DL, et al. HPA-1a phenotype-genotype discrepancy reveals a naturally occurring Arg93Gln substitution in the platelet beta 3 integrin that disrupts the HPA-1a epitope. Blood 2002;99:1833-1839
35. Hessner MJ, Agostini TA, Bellissimo DB, Endean DJ, Pircon RA, Kirschbaum NE. The sensitivity of allele-specific polymerase chain reaction can obviate concern of maternal contamination when fetal samples are genotyped for immune cytopenic disorders. Am J Obstet Gynecol 1997;176:327-333
36. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;1:363-366
37. Davoren A, Curtis BR, Aster RH, McFarland JG. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004;44:1220-1225
38. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998;92:2280-2287
39. Daniels G, Finning K, Martin P, Soothill P. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004;87:225-232
40. Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol 2007;136:366-378
41. Berkowitz RL, Bussel JB, McFarland JG. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol 2006;195:907-913
42. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006;107:91-96
43. Berkowitz RL, Lesser ML, McFarland JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol 2007;110:249-255
44. Bussel JB, Berkowitz RL, McFarland JG. Maternal IVIG in neonatal alloimmune thrombocytopenia. Br J Haematol 1997;98:493-494
45. Flug F, Karpatkin M, Karpatkin S. Should all pregnant women be tested for their platelet PLA (Zw, HPA-1) phenotype? Br J Haematol 1994;86:1-5
46. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007;110:833-839
47. Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007;114:588-595
48. McFarland JG. Post-transfusion purpura. In: Popovsky MA, ed. Transfusion Reactions. 3rd ed. Bethesda, MD: AABB Press; 2007:275-294
49. Slichter SJ. Algorithm for managing the platelet refractory patient. J Clin Apher 1997;12:4-9
50. Benson K. Criteria for diagnosing refractoriness to platelet transfusions. In: Kickler TS, Herman JH, eds. Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunity. Bethesda, MD: AABB Press; 1999:33-55
51. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000;14:180-196
52. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-205
53. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-387
54. Alcorta I, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol 1996;93:220-224
55. McFarland JG, Anderson AJ, Slichter SJ. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol 1989;73:380-386
56. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869
57. Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41:766-770
58. Taaning E, Simonsen AC, Hjelms E, Svejgaard A, Morling N. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients. Vox Sang 1997;72:238-241
59. Langenscheidt F, Kiefel V, Santoso S, Mueller-Eckhardt C. Platelet transfusion refractoriness associated with two rare platelet-specific alloantibodies (anti-Baka and anti-PlA2) and multiple HLA antibodies. Transfusion 1988;28:597-600
60. Chong BH, Ho SJ. Autoimmune thrombocytopenia. J Thromb Haemost 2005;3:1763-1772
61. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580-587
62. Nurden AT. Polymorphisms and platelet genotyping: the shape of things to come. J Thromb Haemost 2006;4:1194-1196
63. Ouwehand WH. Platelet genomics and the risk of atherothrombosis. J Thromb Haemost 2007;5(Suppl 1):188-195
64. Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM. Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 2007;109:1862-1869
65. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-1094
66. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000;7:284-289
67. Benze G, Heinrich J, Schulte H, et al. Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J 2002;23:325-330
68. Muller TH, Doscher A, Schunter F. Genotyping of the human platelet antigen-1 by ELISA detection of allele-specific amplicons. Vox Sang 1997;73:185-188
69. Legler TJ, Kohler M, Mayr WR, Panzer S, Ohto H, Fischer GF. Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing. Transfusion 1996;36:426-431
70. Meyer O, Abou-Chaker K, Heymann G, Bombard S, Kiesewetter H, Salama A. Human platelet antigen genotyping by using sequence-specific primers and the particle gel agglutination assay. Vox Sang 2005;88:271-274